Deventer, August 7, 2019 – Today a first clinical QuiremScout® patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor in Petten, the Netherlands. QuiremScout® is an innovative product for screening liver cancer patients before they are treated with QuiremSpheres®.
“We are very pleased that after a period of extensive testing and validation, we can now use the NRG reactor for clinical productions.” says Jan Sigger, CEO of Quirem Medical. “NRG has proven to be a strong partner and we value their commitment during the development process leading up to this first clinical case. With the high availability and reliability of the NRG reactor, we are confident we can meet the strongly increasing demand for our products throughout Europe and beyond.”
“NRG is an internationally operating nuclear service provider, based in the Netherlands. NRG has a long-standing tradition of partnering with healthcare companies to produce medical isotopes. We are excited that we are now also able to support the production of holmium-166 microspheres, a true Dutch innovation.” says Huub Cuijpers, CEO of NRG.
QuiremScout® is a unique product that allows for screening of patients that are candidates for Selective Internal Radiation Therapy (SIRT). QuiremScout® is unique, as it is the only CE-marked product on the market for that purpose. It is more predictive than the current standard, Tech-99m-MAA.
QuiremSpheres®, the next generation of radio-embolization microspheres, is the only commercially available SIRT product that contains holmium-166 microspheres. Unlike the widely adopted Yttrium-90 microspheres, holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.